

CURRICULUM VITAE

Luis António Marques da Costa

Date of Birth: June 8, 1961



Present Titles and Affiliation

Director of the Oncology Department at Hospital de Santa Maria, Lisbon, Portugal

Associate Professor of Medicine, Oncology & Oncobiology, FML-UL

Principal Investigator & Head of Translational Oncobiology Lab, Institute of Molecular Medicine, Lisbon

Director of the Clinical Research Center at Lisbon Academic Medical Center (CAML)

Office Address

Serviço de Oncologia do Hospital de Santa Maria, Piso 3, 1649-035 Lisboa

Phone: +351 217805096; Fax: +351 217805615

E-mail: luis.costa@chln.min-saude.pt; luiscosta.oncology@gmail.com

Research Focus

My interests in clinical research have been focus in the area of bone metastases (BM) since 1995. In a cooperative project between the Hospital de Santa Maria in Lisbon and Dr. Allan Lipton Lab at the Penn State University, USA, we tested the clinical value of type I bone collagen fragments to monitor treatment response in patients with BM, showing that these are useful biochemical biomarkers of response in clinical trials testing new drugs to treat BM. We also disclosed the role of matrix metalloproteinases (MMPs) in osteoclast independent mechanisms of bone degradation, and are particularly interested in testing the role of MMP-1-derived collagen fragments as growth/survival factors for cancer cells.

Over the years, we have been collaborating with Prof. Rakesh Kumar, former chairman of Department of Molecular & Cellular Oncology at M. D. Anderson Cancer Center, USA, in research projects focusing in breast cancer. Our cooperative efforts led to the identification of the correlation between lymph node metastases and the expression of paxillin in tumors. Ongoing projects focus on triple negative breast cancer and synchronous bilateral breast cancer, as part of the Global Cancer Genomics Consortium activities.

At our research unit at the Institute of Molecular Medicine, we have ongoing projects aiming to understand the relationship between estrogen dependence and cancer cell tropism to bone; and the role of phospholipase C family in colorectal cancer progression.

In the Oncology Division at Hospital de Santa Maria I am deeply involved in clinical research. In the last two years I was the PI in 17 clinical trials in breast cancer and bone metastases. In 2016 our division had 27 active clinical trials, spanning the majority of tumor types.

Education

- MD, FML-UL, University of Lisbon 1985
- PhD in Medical Oncology, FML-UL, University of Lisbon 2002

Professional Training – Hospital Appointments

- Internship, Hospital de Santa Maria, Lisbon 1986-1987
- Residency and Fellowship in Internal Medicine, Hospital de Santa Maria 1988-1990
- Fellowship in Medical Oncology, Hospital de Santa Maria and IPO Lisbon 1990-1993
- Visitor fellow at Hershey Medical Center, Penn State University, PA, USA 1992
- Assistant Physician, Oncology Division, Hospital de Santa Maria 1993-1998
- Consultant in Internal Medicine, Hospital de Santa Maria 1999
- Consultant in Oncology, Hospital de Santa Maria 1999
- Chief in Oncology, Oncology Division, Hospital de Santa Maria 2009-2012
- Director of the Oncology Department, Hospital de Santa Maria 2005-present
- Coordinator of the Oncology Committee, Hospital de Santa Maria 2013-present
- Director of the Clinical Research Center, Hospital de Santa Maria 2016-present

Academic Appointments

- Assistant Professor of Medicine, FML-UL 1995-2002
- Principal Investigator, Institute of Molecular Medicine (IMM) 2002-present
- Visiting Professor, M.D. Anderson Cancer Center, USA 2003, 2004
- Head of Translational Oncobiology Research Unit (IMM) 2007-present
- Board Directors, Master Course in Palliative Medicine, FML-UL 2004-present
- Coordinator Professor of Oncobiology, FML-UL 2009-present
- Editorial Board, Harvard Medical School Program Portugal 2011 - present
- Board Directors, Master Course in Oncobiology, FML-UL 2012 – present
- President, Portuguese Association of Cancer Research (ASPIC) 2016-present

Professional Certification

- Portuguese Board of Internal Medicine
- Portuguese Board of Medical Oncology
- European Society of Medical Oncology (ESMO)

Member of Medical and Scientific Societies

- Direction Committee, Portuguese Society of Oncology 2003-2005
- Portuguese Head, Global Cancer Genomics Consortium 2011-2016
- Scientific Program Committee, 12th International CIBD Meeting 2012
- Portuguese Association of Cancer Research (ASPIC), President 2016-present
- Scientific Program Committee, Metastatic Breast Cancer, ESMO Meeting 2016
- National Committee, Oncology Reference Centers, Portuguese Government 2016
- Member, Portuguese Board of Internal Medicine
- Member, Portuguese Board of Medical Oncology
- Member, American Society of Medical Oncology (ASCO)
- Member, European Society of Medical Oncology (ESMO)
- Member, European Association for Cancer Research (EACR)

International Advisory Boards in Bone Metastases

Since 2001 Dr. Costa is regularly invited to participate in International Advisory Boards as an expert in bone metastases field and in the treatment of breast cancer. During these meetings Dr. Costa is called to provide his input in the development of scientific research programs (translational research and clinical studies) regarding new therapeutic targets.

Expert Reviewer for Funding Agencies and Grants

- European Research Council (ERC)
- Cancer Research UK, UK
- CAIBER, Spanish Clinical Research Network, Spain
- French National Cancer Institute, France
- INSERM, France
- Innovational Research Incentives Scheme – Vidi, The Netherlands
- LPCC, Portugal
- Laço, Portugal
- FCT, Portugal

Editorial Boards and Peer Reviewer

Journal of Bone Oncology; PloS One; *ecancermedicalsecience*; Annals of Oncology; Bone; British Journal of Cancer; Critical Reviews in Oncology/Hematology; Cancer Letters; European Journal of Cancer; Breast Cancer Research and Treatment; The Oncologist; Cancer Treatment Reviews; Therapeutic Advances in Medical Oncology; The Breast; Lancet Oncology; Drugs; Lancet; Oncotarget.

Clinical Research as PI or Co-Investigator (only trials open in 2016-present)

- **Trax-Her** A Phase II, Randomized, Open-label study of trastuzumab emtansine and Capecitabine VS Trastuzumab emtasine alone in HER2 positive metastatic breast cancer
- **Berenice** A Phase II, multicenter, study to evaluate pertuzumab in combination with Trastuzumab and standard neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, Inflammatory, or early-stage breast cancer
- **SandPiper** A phase III, double-blind, placebo-controlled, randomized study of taselisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy
- **PERUSE** A multicenter open-label single-arm study of pertuzumab in combination with trastuzumab and a taxane in the first-line treatment of patients with her2-positive advanced (metastatic or locally recurrent) breast cancer
- **ICORG** A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer.
- **Brocade** A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA Associated Breast Cancer
- **Bolero 4** A Phase II, open label, single-arm, everolimus in combination with letrozole for the treatment of postmenopausal women with metastatic or locally advanced breast cancer positive for estrogen receptors and HER2 negative
- **TnAcity** A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly nab[®]-Paclitaxel in Combination with Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin as First Line Treatment in Subjects with ER, PgR, AND HER2 Negative (Triple Negative)
- **Metapher** A multicenter, open-label, single-arm safety study of Herceptin SC in combination with Perjeta and Docetaxel in treatment of patients with Her2-positive advanced breast cancer (metastatic or locally recurrent)
- **Sophia** A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment
- **TempoBreast** A Phase II, randomised, Study comparing, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with Advanced Breast Cancer
- **Samantha** European disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-Positive unresectable locally advanced or metastatic breast cancer

- **NEMO** A phase III, multicenter, randomized study with two arms and open label, compared MEK162 the efficacy of dacarbazine in patients with advanced unresectable metastatic melanoma or positive for the mutation NRAS
- **COLUMBUS** A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma
- **Meteor (XL184)** A Phase 3, Randomized, Controlled Study of Cabozantinib (XL 184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
- **PCR4011** Non-interventional prospective multicenter study registry of patients with a confirmed diagnosis of metastatic prostate adenocarcinoma resistant to castration

Pre-Clinical Research Support as PI or Co-Investigator

- PI, 2016/2017, Molecular Markers of Bone Metastases, Agency: Private Donation
- PI, 2016/2016, CORBIE - Characterizing the biological role of clinically relevant collagen type I fragments in metastatic breast cancer. Agency: Celgene Sociedade Unip., Lda.
- PI, 2015/2018, Analysis of RANK protein expression in Cohort 2 using immunohistochemistry (IHC) in 70 matched primary breast cancer tumors and distant metastasis. Agency: Amgen Inc.
- PI, 2015/2016, IMM Bridge Grant 2015, Agency: Fundação para a Ciência e a Tecnologia
- PI, 2013/2016, Molecular Characterization of Breast Cancers, Agency: Novartis Farma, S.A.
- PI, 2013/2016, Collagen in Breast cancer, Agency: Celgene Sociedade Unip., Lda.
- PI, 2013, Global Cancer Genomic Consortium. Agency: Astrazeneca
- PI, 2013, GCGC Meeting. Agency: FCT-FACC
- PI, 2012/2013, Long Term Bisphosphonates. Agency: Novartis
- PI, 2012/2013, Educational Program in Oncobiology. Agency: Fundação Calouste Gulbenkian
- PI, 2012/2013, Cachexia in pancreatic cancer. Agency: Pfizer
- PI, 2012/2013, Activation of mTOR pathway in breast cancer: analysis of primary and metastasis tumor samples. Agency: Novartis
- PI, 2009/2012, Prognostic Signatures in Colorectal Cancer (PIC/IC/82821/2007). Agency: Fundação para a Ciência e a Tecnologia
- PI, 2008/2017, Oncology Series. Agency: Novartis, Pfizer
- PI, 2008/2014, Senescence in rectal cancer. Agency: Merck, SA.
- Co-Investigator, 2016/2019, PERSEIDS - Personalizing cancer therapy through integrated modeling and decision (PTDC/EMS-SIS/0642/2014). Agency: Fundação para a Ciência e a Tecnologia
- Co-Investigator, 2016/2018, Involvement of PLCY1 in the resistance Mechanism to Anti-EGFR Therapy in Metastatic Colorectal Cancer. Agency: Liga Portuguesa Contra o Cancro

- Co-Investigator, 2016/2017, The prognostic role of RANK SNP rs34945627 in breast cancer patients. Agency: Fundo iMM/Laço
- Co-Investigator, 2016/2017, Involvement of PLCg1 in resistance to anti EGFR therapy in colorectal cancer. Agency: Grupo de Investigação do Cancro Digestivo
- Co-Investigator, 2015/2016, Luminal-type breast cancer: prognostic value of RANK-positive lymphatic nodes. Agency: Astrazeneca
- Co-Investigator, 2014/2016, Relative effectivity of aromatase inhibitors versus tamoxifen in patients with early breast cancer (HMSP-ICJ/0007/2013). Agency: Fundação para a Ciência e a Tecnologia
- Co-Investigator, 2014/2016, Mechanisms of invasion and progression of cancer in bone: Molecular profiling of matrix and adhesion-related molecules in metastatic disease, Agency: Liga Portuguesa Contra o Cancro
- Co-Investigator, 2013/2016, Molecular and Nano Systems for Theranostics in Cancer (EXCL/QEQ-MED/0233/2012), Co-Investigator, Agency: Fundação Ciência e Tecnologia
- Co-Investigator, 2013/2015, Metal-based Multimodal Probes for Breast Cancer Imaging Targeting Y1-NPY Receptors: Synthesis, Characterization and Pre-clinical Evaluation (FCT-ANR/QEQ-MED/0117/2012). Agency: Fundação para a Ciência e a Tecnologia
- Co-Investigator, 2013/2014, c-Met, p-c-Met, and HGF IHC in Bone Metastases. Agency: Merck, S.A.
- Co-Investigator, 2011/2014, Multi-Functional Bone Seeking Agents for the Treatment of Skeletal Metastatic Disease (PTDC/SAU-OB/108608/2008). Agency: Fundação para a Ciência e a Tecnologia
- Co-Investigator, 2011/2014, Multi-Functional Bone Seeking Agents for the Treatment of Skeletal Metastatic Disease (PTDC/QUI-QUI/115712/2009). Agency: Fundação para a Ciência e a Tecnologia
- Co-Investigator, 2011/2014, Molecular markers in multiple myeloma. Agency: Grupo Hematológico Português
- Co-Investigator, 2011/2014, Mechanisms of invasion and progression in metastatic bone disease and outcomes in HER2 positive metastatic breast cancer (HMSP-ICS/0004/2011). Agency: Harvard Medical School
- Co-Investigator, 2011/2012, D-dimmers in gastric cancer. Agency: Sanofi Aventis

Supervision Experience

- Master Thesis in Palliative Care, Manuel Luís Capela, *Dor total nos Doentes com Metastização Óssea*, FML-UL, 2006, Supervisor
- Master Thesis in Palliative Care, Tânia Marisa Abreu Jardim, *Competências dos enfermeiros para cuidar do coente em cuidados paliativos*, FML-UL, 2007, Supervisor
- Master Thesis in Palliative Care, Timothy Francisco Lima, *Cuidar do doente terminal em ensino clinico - o desenvolvimento de competências*, FML-UL, 2007, Supervisor

- Master Thesis in Biomedical Engineering, Inês Nunes de Sousa, *Ultrasound Contrast Agents for in situ Drug Delivery*, IST, 2007, Co-Supervisor
- Master Thesis in Biomedical Engineering, Vanda Manha Rodrigues Marques, *Classificação de doentes com cancro, em categorias de risco, no desenvolvimento de complicações em metástases ósseas*, IST, 2007, Co-Supervisor
- PhD Thesis in Biomedical Sciences, Irina Alho, *The importance of Low Molecular Weight Protein Tyrosine Phosphatase in the progression of metastatic bone disease and therapeutic reponse*, FML-UL, 2013, Supervisor
- PhD Thesis in Biomedical Sciences, Joana Tato-Costa, *Effects of chemotherapy and radiotherapy in rectal cancer: significance of different cellular outcomes in tumour behavior*, FML-UL, 2015, Supervisor
- Master Thesis in Clinical Research and Regulatory Affairs for Drugs, Biologics, and Medical Devices, Arlindo Ferreira, *The influence of menopausal status on bone turnover and disease control in breast cancer patients with metastatic bone disease treated with chemotherapy plus zoledronic acid: an exploratory retrospective cohort study*, Nova Medical School & Northeastern University, 2015, Supervisor

Ongoing Thesis

- PhD Thesis in Medicine, Arlindo Ferreira, *Patterns of Care and Comparative Effectiveness of Endocrine Therapy for Breast Cancer*, FML-UL, Supervisor
- PhD Thesis in Medicine, Inês Vaz Luis, *Padrões de tratamento e outcomes em doentes com cancro da mama com menos de 1cm (T1a-bNOMO)*, FML-UL, Supervisor
- Master Thesis in Oncobiology, Inês Vendrell, *Pesquisa de alterações moleculares ao nível do DNA de doentes com cancro da mama estadio IV*, Supervisor
- Master Thesis in Oncobiology, Catarina Pulido, *Análise retrospectiva da expressão génica de carcinomas invasivos da mama em estadio precoce para estratificação do risco de recidiva*, Supervisor
- Master Thesis in Oncobiology, António Araújo Pereira, *Pancreatic stellate cells and miR-21: partners in crime?*, FML-UL, Supervisor
- Master Thesis in Oncobiology, Ysel Chiara Rodrigues, *MicroRNA profiling in hematogenous colorectal cancer dissemination*, FML-UL, Supervisor

Member of Medical and Academic Jurys

- Internal Medicine Residency Jury, 1996, 1997 and 1999
- Master Thesis in Molecular Medicine, Maria Fernanda Milanezi, *Avaliação do Her-2 em carcinomas invasivos da mama: correlação entre estudo imunohistoquímico e hibridização in situ por fluorescência*, UP, 2004, Arguer
- Master Thesis in Palliative Care, Maria Amorim Cerqueira, *O cuidador e o doente paliativo no Alto Minho*, FML-UL, 2004, President of Jury
- Master Thesis in Psychosomatic, Ana Cristina Charraz, *Abordagem psicossomática da ansiedade e depressão em doentes oncológicos – Estudo Epidemiológico*, ISPA, 2005, Arguer

- Consultant in Medical Oncology Curricula Evaluation, Direcção Geral de Saúde, 2004
- Master Thesis in Oncology, Ana Paula Soares Santos, *Falência dos Mecanismos de Regulação Endócrina na Obesidade e sua relação com a Carcinogénese Mamária*, Instituto de Ciências Biomédicas Abel Salazar, 2005, Arguer
- Consultant in Medical Oncology, Teresa Fiúza, Hospital Fernando da Fonseca, 2005, Member of Jury
- PhD Thesis, Felismina Luísa G. Queiroga, *Tumores Mamários da Cadela*, Universidade de Tás-os-Montes e Alto Douro, 2005, Arguer
- Master Thesis in Bioethics, Sandra Manuela Serrano, *Atitude dos profissionais de saúde perante a problemática ética do fim da vida*, FML-UL, 2005, President of Jury
- PhD Thesis in Human Biology, Lara Cristina Sayanda, *Estudo das Alterações Genéticas envolvidas na via da Carcinogénese do Cancro do Cólon e Recto associada à Colite Ulcerosa*, O'Porto Medical School, 2005, Member of Jury
- Master Thesis in Bioethics, Olívia Rego Tavares, *Ética da Gestão de Recursos em Geriatria*, FML-UL, 2005, President of Jury
- Master Thesis in Palliative Care, Emanuela Santos Andrade, *A necessidade de uma Unidade de Cuidados Paliativos no Distrito de Santarém*, FML-UL, 2005, President of Jury
- Master Thesis in Palliative Care, Maria de Fátima Azevedo, *A Medicina Geral e Familiar e o Luto*, FML-UL, 2005, President of Jury
- PhD Thesis in Biomedical Sciences, Joana G. Brandão, *Bone Marrow as Sanctuary for Breast Cancer Cells: Identification of New Targets for Therapeutic Intervention in Micrometastatic Disease*, FML-UL, 2006, Arguer
- Medical Oncology Residency, Ana Barros Pinto, 2006, Arguer
- PhD Thesis in Biomedical Sciences, Raquel Ferreira Rodrigues, *Alterações genéticas associadas ao processo de carcinogénese do tumor de origem folicular na glândula tiroideia*, FML-UL, 2007, Jury Member
- Master Thesis in Palliative Care, Maria Georgiana Gama, *Validação de uma escala de satisfação de doentes*, FML-UL, 2007, President of Jury
- PhD Thesis in Biomedical Sciences, Marta Elisa Dias Agostinho, *Human Topoisomerase I in Chromatin based phenomena*, FML-UL, 2007, Jury Member
- Medical Oncology Residency, 2007, Member of National Jury
- Master Thesis in Palliative Care, Lucinda Maria da Silva Marques, *Qualidade de vida dos doentes terminais oncológicos em internamento e em ambulatório*, FML-UL, 2009, President of Jury
- Master Thesis in Palliative Care, Maria Flávia Silva e Sousa, *Tradução e adaptação linguística e cultural para português do Liverpool Care Pathway*, FML-UL, 2010, President of Jury
- Master Thesis in Palliative Care, Filipa Gonçalves Tavares, *Acuidade prognóstica em fim de vida – valor preditivo de quatro métodos na estimativa de sobrevivência de doentes oncológicos de um hospital central e universitário português*, FML-UL, 2010, President of Jury

- PhD Thesis in Biomedical Sciences, Célia Maria Freitas Gomes, *Avaliação funcional de resistência a múltiplos fármacos em tumores sólidos: modelos in vitro e in vivo*, UC, 2011, Arguer
- PhD Thesis in Medicine, Catarina Sofia Granja da Fonseca, *The role of systemic metabolism in breast cancer progression*, FML-UL, 2014, Arguer
- PhD Thesis in Medicine, Daniela Dias-Santos, *Analysis of outcome and cancer stem cells status in patients with resectable pancreatic adenocarcinoma*, Nova Medical School, 2015, Arguer
- PhD Thesis in Neurosciences, Susana Filipa Pereira, *Neurological Complication of Breast Cancer*, UPI, 2015, Arguer
- PhD Thesis in Biomedical Sciences, Dusan Djokovic, *The Role of the DELTA-LIKE 4 NOTCH Ligand in Tumor Angiogenesis*, FML-UL, 2011, Arguer
- PhD Thesis in Biomedical Sciences, Ana Barbosa Nogal, *Proteomic Characterization of Lung Cancer and Chronic Obstrutive Pulmonary Disease: A bronchoalveolar lavage fluid analysis*, UPI, 2014, Arguer
- PhD Thesis in Biomedical Sciences, Maria Amélia Pereira, *Importância clínica de novos marcadores moleculares no cancro colorectal*, UC, 2014, Arguer
- PhD Thesis in Biomedical Sciences, Maria João Leal Carvalho, *Células Estaminais do Cancro do Endométrio: Caracterização, resposta à terapêutica e padrão de metastização in vivo*, UC, 2015, Arguer
- Master Thesis in Oncobiology, Ana Isabel da Silva Vieira, *Prospective analysis of regulatory T cell homeostasis after allogeneic hematopoietic stem cell transplantation*, FML-UL, 2015, President of Jury
- Master Thesis in Oncobiology, Carolina Isabel Garcia Cardina, *Low doses of ionizing radiation induce angiogenesis after radiotherapy*, FML-UL, 2015, President of Jury
- Master Thesis in Oncobiology, Sara Santos Henriques, *Luminal-type breast cancer: prognostic value of RANK-positive lymphatic nodes RANK+ luminal breast cancer in vitro approach*, FML-UL, 2015, President of Jury
- Master Thesis in Oncobiology, Diana Domingos de Matos, *Synthesis, characterization and biological assessment of multi-functional bone-seeking agents. Evaluation of the effects of new compounds in breast and prostate cancer cell lines, cell outcome and assessment of the mechanisms of action*, FML-UL, 2015, President of Jury
- Master Thesis in Palliative Care, Ana Mafalda Mendes, *Qualidade de Vida em Doentes com Metastases Ósseas: Validação da Escala EOTC QLQ BM22*, FML-UL, 2015, President of Jury
- PhD Thesis in Medical Sciences, Antonio Miguel Henriques da Cunha Abreu, *Male breast cancer: Prognostic and predictive factors of response to therapy*, UP, 2015, Arguer
- PhD Thesis in Management, Isabel Borges da Costa, *Strategic Management of New Drugs in Oncology – The Importance of an Ethical and Interdisciplinary Framework*, ISCTE-IUL, 2016, Jury Member

- Master Thesis in Oncobiology, Inês Correia, *Analysis of the effect of the over-expression of receptor activator of NF- κ B (RANK) in estrogen receptor-positive breast cancer cells over tumour behaviour in vivo*, FML-UL, 2017, President of Jury
- Master Thesis in Oncobiology, Raquel Duarte, *Role of PLC γ 1 in the Resistance Mechanism to Anti-EGFR Therapy in Metastatic Colorectal Cancer*, FML-UL, 2017, President of Jury
- Master Thesis in Oncobiology, Ana Duarte, *The DNA damage response in terminally differentiated skeletal myotubes*, FML-UL, 2017, President of Jury

Full List of Publications

http://scholar.google.pt/citations?view_op=list_works&hl=pt-PT&user=FGbHHOMAAAAJ

1. von Moos, R., Costa, L., Ripamonti, C. I., Niepel, D. & Santini, D. Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain. *European journal of cancer* 71, 80-94 (2017).
2. Pulido, C. et al. Bone metastasis risk factors in breast cancer. *Ecancermedicalsecience* 11 (2017).
3. Ferreira, A. et al. Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases. *J Bone Oncol* 6, 16-21 (2017).
4. Tato-Costa, J. et al. Therapy-induced cellular senescence induces epithelial-to-mesenchymal transition and increases invasiveness in rectal cancer. *Clinical colorectal cancer* 15, 170-178. e173 (2016).
5. Ribeiro, E. et al. Radiolabeled block copolymer micelles for image-guided drug delivery. *International Journal of Pharmaceutics* 515, 692-701 (2016).
6. Mansinho, A., Ferreira, A. R. & Costa, L. Hypocalcemia in patients with metastatic bone disease treated with denosumab. *Annals of Joint* 1 (2016).
7. Fiuza, M. et al. Organização e implementação de uma consulta de cardio-oncologia. *Revista Portuguesa de Cardiologia* 35, 485-494 (2016).
8. Fiuza, M. et al. Organization and implementation of a cardio-oncology program. *Revista Portuguesa de Cardiologia (English Edition)* 35, 485-494 (2016).
9. Ferreira, A. R. et al. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study. *The Breast* 29, 68-73 (2016).
10. Ferreira, A. R. et al. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskelatal Metastases. *The oncologist* 21, 1418-1426 (2016).
11. Ferreira, A. et al. The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. *Oncotarget* 7, 41380 (2016).
12. Costa, L. in *Medicine*. (LIPPINCOTT WILLIAMS & WILKINS TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA).
13. Coelho, R. M. et al. Dynamic modeling of bone metastasis, microenvironment and therapy: integrating parathyroid hormone (PTH) effect, anti-resorptive and anti-cancer therapy. *Journal of theoretical biology* 391, 1-12 (2016).
14. Chowdhury, S. et al. in Poster presented at the American Society of Clinical Oncology (ASCO) 2016 Congress.
15. Chow, L. W. et al. Cancer Genomics and Biology 2015–Meeting Report. *Genes & cancer* 7, 1 (2016).

16. Casimiro, S., Ferreira, A. R., Mansinho, A., Alho, I. & Costa, L. Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? *International journal of molecular sciences* 17, 1415 (2016).
17. Casimiro, S. et al. Phosphorylated YB-1 (Y-box binding protein 1) as a biomarker of poor prognosis in patients with breast cancer. *European journal of cancer* 61, S198 (2016).
18. Body, J.-J. et al. Health resource utilization associated with skeletal-related events: results from a retrospective European study. *The European Journal of Health Economics* 17, 711-721 (2016).
19. Alho, I., Costa, L., Bicho, M. & Coelho, C. Low Molecular Weight Protein Tyrosine Phosphatase Slow Isoform Knockdown in MDA-MB-435 Cells Decreases RAW 264.7 Osteoclastic Differentiation. *Anticancer research* 36, 2227-2232 (2016).
20. Vendrell, I. et al. in *INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER*. 212-212 (LIPPINCOTT WILLIAMS & WILKINS TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA).
21. Vendrell, I., Macedo, D., Alho, I., Dionísio, M. & Costa, L. Treatment of cancer pain by targeting cytokines. *Mediators of inflammation* 2015 (2015).
22. Toi, M. et al. The global cancer genomics consortium's symposium: new era of molecular medicine and epigenetic cancer medicine-cross section of genomics and epigenetics. *Genes & cancer* 6, 1 (2015).
23. Ribeiro, C. et al. in *NEUROENDOCRINOLOGY*. 96-96 (KARGER ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND).
24. Rebelo Ferreira, A. et al. in *European journal of cancer*. S320-S320 (ELSEVIER SCI LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND).
25. Pacheco, T. R. et al. (American Society of Clinical Oncology, 2015).
26. Mendes, D. et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer—a systematic review. *Breast Cancer Research* 17, 140 (2015).
27. Matias, M. et al. Prognostic factors after liver resection for colorectal liver metastasis. *Acta medica portuguesa* 28, 357-369 (2015).
28. Magalhaes, A. A. et al. Early changes in left ventricular diastolic function after chemotherapy predict subsequent Nt-probnp elevation in breast cancer patients. *European Journal of Heart Failure* 17, 72 (2015).
29. Magalhaes, A. A. et al. Longitudinal global strain as a predictor of cardiotoxicity in breast cancer patients. *European Journal of Heart Failure* 17, 25 (2015).
30. Magalhaes, A. et al. in *EUROPEAN HEART JOURNAL*. 704-704 (OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND).
31. Hadji, P. et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *Ann Oncol*, mdv617 (2015).
32. Ferreira, A. R. et al. 1962 The use of trastuzumab in patients with early breast cancer: A multi-institutional study. *European journal of cancer* 51, S320 (2015).
33. Ferreira, A. R., Abrunhosa-Branquinho, A., Jorge, M., Costa, L. & Vaz-Luís, I. in *International Manual of Oncology Practice* 867-889 (Springer, 2015).
34. Ferreira, A. et al. 1965 Patterns of care and relative effectiveness of aromatase inhibitors compared to tamoxifen in patients with early breast cancer: A multi-institutional study. *European journal of cancer* 51, S322 (2015).
35. Ferreira, A., Alho, I., Casimiro, S. & Costa, L. Bone remodeling markers and bone metastases: from cancer research to clinical implications. *BoneKEy reports* 4 (2015).

36. Costa, A. L. et al. Prevention of nausea and vomiting in patients undergoing oral anticancer therapies for solid tumors. *BioMed research international* 2015 (2015).
37. Chowdhury, S. et al. The Prostate Cancer Registry: First results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC). *Target* 1000, 1500 (2015).
38. Chowdhury, S. et al. 2548 The Prostate Cancer Registry: First results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC). *European journal of cancer* 51, S492 (2015).
39. Chowdhury, S. et al. The Prostate Cancer Registry: analysis of medical resource utilisation (Mru) in an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (Mcrpc). *Sort* 100, 250 (2015).
40. Cardiga, R. et al. Intoxicação por monóxido de carbono com compromisso cardíaco: o que sabemos? *Revista Portuguesa de Cardiologia* 34, 557. e551-557. e555 (2015).
41. Cardiga, R. et al. What do we know about carbon monoxide poisoning and cardiac compromise? Treatment and prognosis. *Revista Portuguesa de Cardiologia (English Edition)* 34, 557. e551-557. e555 (2015).
42. Body, J.-J., Casimiro, S. & Costa, L. Targeting bone metastases in prostate cancer: improving clinical outcome. *Nature Reviews Urology* 12, 340-356 (2015).
43. Marques, F. et al. The role of iron deficiency with or without anemia as a predictor of readmission in heart failure. *European Journal of Heart Failure* 16, 151 (2014).
44. Marques, F. et al. Prevalence of sleep-disordered breathing in acute heart failure: preliminary results. *European Journal of Heart Failure* 16, 43 (2014).
45. Magalhaes, A. et al. Nt-probnp and myocardial deformation analysis by speckle tracking are useful for early risk stratification of cardiotoxicity. *European Journal of Heart Failure* 16, 219 (2014).
46. Lipton, A., Costa, L., Sieber, P., Dougall, W. C. & Braun, A. in *Bone Metastases* 235-246 (Springer, 2014).
47. Henry, D. et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. *Supportive Care in Cancer* 22, 679-687 (2014).
48. Fizazi, K. et al. 869 Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid. *European Urology Supplements* 1, e869-e869a (2014).
49. Fernandes, C. et al. Biological assessment of novel bisphosphonate-containing ^{99m}Tc/Re-organometallic complexes. *Journal of Organometallic Chemistry* 760, 197-204 (2014).
50. Costa, L. et al. The global cancer genomics consortium's third annual symposium: From oncogenomics to cancer care. *Genes & cancer* 5, 64 (2014).
51. Costa, L. Which bisphosphonate to treat bone metastases? *The Lancet Oncology* 15, 15-16 (2014).
52. Costa, L. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference. *Current opinion in supportive and palliative care* 8, 414-419 (2014).
53. Casimiro, S. et al. Metadherin expression and lung relapse in patients with colorectal carcinoma. *Clinical & experimental metastasis* 31, 689-696 (2014).

54. Carmo, J. et al. Prevalence and prognostic impact of iron deficiency with or without anemia in heart failure with reduced and preserved ejection fraction. *European Journal of Heart Failure* 16, 311 (2014).
55. Von Moos, R. et al. in *European journal of cancer*. S268-S268 (ELSEVIER SCI LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND).
56. Silbermann, R. et al. *Journal of Bone Oncology*. (2013).
57. Shan, N. et al. (American Society of Clinical Oncology, 2013).
58. Picarda, G. et al. *Journal of Bone Oncology*. (2013).
59. Pakala, S. B. et al. MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer. *Cancer research* 73, 3761-3770 (2013).
60. Moniz, P. et al. Thyroid disease: Clinical presentation isn't what it used to be. *European Journal of Internal Medicine* 24, e111 (2013).
61. Magalhaes, A. et al. Predictors of cardiotoxicity in breast cancer: value of speckle-tracking analysis. *European Journal of Heart Failure* 12, S249 (2013).
62. Macedo, D. et al. The treatment of liver metastases in patients with neuroendocrine tumors in 2012. *ISRN hepatology 2013* (2013).
63. Kumar, R. et al. The Global Cancer Genomics Consortium's Second Annual Symposium: Genomics Medicine in Cancer Research. *Genes & cancer* 4, 196-200 (2013).
64. Horvath, A. et al. Novel insights into breast cancer genetic variance through RNA sequencing. *Scientific reports* 3 (2013).
65. Ganju, V. et al. Denosumab and zoledronic acid (za) treatment in patients with genitourinary (gu) cancers and bone metastases. *BJU international* 112, 11 (2013).
66. Felix, J., Ferreira, D., Rabiais, S., Vandewalle, B. & Costa, L. in *European journal of cancer*. S415-S415 (ELSEVIER SCI LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND).
67. Costa, L., Lipton, A., Hadji, P., Chen, Y.-M. & Kosmidis, P. Treatment of bone metastases before the onset of pain. *International journal of clinical oncology* 18, 531-538 (2013).
68. Costa, L. et al. (American Society of Clinical Oncology, 2013).
69. Coleman, R. E. et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials. *J Bone Oncol* 2, 70-76 (2013).
70. Coleman, R. et al. *Journal of Bone Oncology*. (2013).
71. Casimiro, S. et al. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. *PloS one* 8, e63153 (2013).
72. Casimiro, S. et al. RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (IAPs) in RANK-positive breast cancer cells. *J Bone Oncol* 2, 116-122 (2013).
73. Caiado, J. et al. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. *The Journal of Allergy and Clinical Immunology: In Practice* 1, 494-500 (2013).
74. Alho, I., Costa, L., Bicho, M. & Coelho, C. Low molecular weight protein tyrosine phosphatase isoforms regulate breast cancer cells migration through a RhoA dependent mechanism. *PloS one* 8, e76307 (2013).
75. Alho, I., Costa, L., Bicho, M. & Coelho, C. Characterization of low molecular weight protein tyrosine phosphatase isoforms in human breast cancer epithelial cell lines. *Anticancer research* 33, 1983-1987 (2013).

76. Alho, I., Costa, L., Bicho, M. & Coelho, C. The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis. *Tumor Biology* 34, 1979-1989 (2013).
77. Zubritsky, L. et al. (AACR, 2012).
78. Russell, K., Clemons, M., Costa, L. & Addison, C. L. Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there? *J Bone Oncol* 1, 12-17 (2012).
79. Ravaud, A. et al. Genitourinary tumors, non-prostate. *Ann Oncol* 23, ix258-ix293 (2012).
80. Lipton, A. et al. (American Society of Clinical Oncology, 2012).
81. Lipton, A., Costa, L. & Coleman, R. E. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates? *Breast disease* 33, 59-69 (2012).
82. Hadji, P., Aapro, M., Costa, L. & Gnant, M. Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations. *Cancer treatment reviews* 38, 815-824 (2012).
83. Fernandes, I. et al. Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. *OncoTargets and therapy* 5, 409 (2012).
84. Fallowfield, L. et al. Weighing bone-targeted treatment options for patients with solid tumours and skeletal complications from metastatic disease. *Eur Oncol Haematol* 8, 148-155 (2012).
85. Clemons, M., Russell, K., Costa, L. & Addison, C. L. Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated? *Breast cancer research and treatment* 134, 453-457 (2012).
86. Casimiro, S. et al. Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. *Clinical & experimental metastasis* 29, 155-164 (2012).
87. Amaral, T. M. S., Macedo, D., Fernandes, I. & Costa, L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. *Prostate cancer 2012* (2012).
88. Amaral, T. & Costa, L. Treatment of Liver Metastases in Patients with Neuroendocrine Tumors 2012.
89. Terpos, E., Costa, L., Harper, P., Coleman, R. E. & Lipton, A. Preclinical and clinical evidence suggests that bisphosphonates have anticancer activities both within and outside bone. Early clinical trials of bisphosphonates provided evidence for antimyeloma effects in exploratory analyses in high-risk subsets, and recent trials of zoledronic acid (ZOL) have provided further support of antimyeloma activity The MRC Myeloma IX trial is an innovative 2× 2 factorial. *Critical Reviews in Oncology/Hematology* 77, S24-S30 (2011).
90. Richardson, G. et al. A Number Needed To Treat Analysis Of Denosumab Versus Zoledronic Acid In Patients With Bone Metastases/lesions Secondary To Solid Tumours (other Than Breast And Prostate) Or Multiple Myeloma. *Asia-pacific Journal of Clinical Oncology* 7, 144 (2011).
91. Richardson, G. et al. Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis. *Journal of Clinical Oncology* 29, 9115-9115 (2011).
92. Ribeiro, J. et al. (AACR, 2011).
93. Ribeiro, J. et al. Role of serum HER2 (sHER2) levels to predict acquisition of HER2 overexpression in patients with metastatic lesions of breast cancer with HER2-negative/unknown at the primary site. *Journal of Clinical Oncology* 29, e11114-e11114 (2011).
94. Henry, D. H. et al. Reply to SM Sorscher et al. *Journal of Clinical Oncology* 29, 2736-2737 (2011).

95. Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *Journal of Clinical Oncology* 29, 1125-1132 (2011).
96. Ha, N.-H. et al. Lactoferrin–endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. *Cancer research* 71, 7259-7269 (2011).
97. Fernandes, I., Amaral, T., Macedo, D., Cortes, P. & Costa, L. Opções Terapêuticas em Carcinomas Neuroendócrinos Gastroenteropancreáticos (GEP NETS) Metastáticos. *Revista Portuguesa de Cirurgia*, 47-54 (2011).
98. Felix, J. et al. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. *Value in Health* 14, 499-505 (2011).
99. Costa, L. et al. Expression of matrix metalloproteinase 1 (MMP1) and dickkopf-1 (DKK1) in bone metastatic tissue (BMT) and in serum of patients with bone metastases (BM) from different solid tumors. *Bone* 48, S25-S26 (2011).
100. Costa, L., Harper, P., Coleman, R. E. & Lipton, A. Anticancer evidence for zoledronic acid across the cancer continuum. *Critical reviews in oncology/hematology* 77, S31-S37 (2011).
101. Costa, L. et al. 3044 POSTER Bone Marker Patterns During Long-term Bisphosphonate Therapy for Patients With Bone Metastases. *European journal of cancer* 47, S235 (2011).
102. Coleman, R. et al. Consensus on the utility of bone markers in the malignant bone disease setting. *Critical reviews in oncology/hematology* 80, 411-432 (2011).
103. Casimiro, S. et al. Analysis of a bone metastasis gene expression signature in patients with bone or non-bone metastases from solid tumors. *Journal of Clinical Oncology* 29, e21054-e21054 (2011).
104. Caiado, J. et al. In vitro diagnosis in hypersensitivity to platins. *Allergy: European Journal of Allergy and Clinical Immunology* 66, 5-6 (2011).
105. Body, J. et al. Patients with bone metastases from solid tumours and poor prognostic features may gain survival benefits from zoledronic acid. *Bone* 48, S20-S21 (2011).
106. Ribeiro, S., Casimiro, S., Costa, L. & Moniz, E. in *EUROPEAN JOURNAL OF MEDICAL RESEARCH*. 91-92 (I HOLZAPFEL VERLAG GMBH HARTHAUSER STR 105, 81545 MUNICH, GERMANY).
107. Ribeiro, J. et al. 195 Correlation between hormonal receptors and HER2 status of primary and metastatic breast cancer according to the metastatic organ involved. *European Journal of Cancer Supplements* 8, 114 (2010).
108. Luís, I. V., Casimiro, S., Ribeiro, J. & Costa, L. Zoledronic Acid: Its Use in the Treatment of Breast Cancer. *Clinical Medicine Insights. Therapeutics* 2, 913 (2010).
109. Luis, I. et al. in *Ann Oncol*. 218-218 (OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND).
110. Lipton, A. et al. Phase I trial of zoledronic acid+ imatinib mesylate (Gleevec) in patients with bone metastases. *American journal of clinical oncology* 33, 75-78 (2010).
111. Henry, D. et al. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. *Journal of Clinical Oncology* 28, 9133-9133 (2010).
112. Glennane, A. et al. Denosumab Delays Skeletal-related Events In Patients With Solid Tumour-related Bone Metastases: A Randomized Phase 3 Study Versus Zoledronic Acid. *Asia-pacific Journal of Clinical Oncology* 6, 166 (2010).

113. Fernandes, I. et al. in *Ann Oncol.* 264-265 (OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND).
114. Costa, L. et al. in *Bone.* S302-S303 (ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA).
115. Costa, L. et al. in *Ann Oncol.* 43-43 (OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND).
116. Costa, L. et al. in *Bone.* S302-S302 (ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA).
117. Casimiro, S. et al. in *Bone.* S299-S299 (ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA).
118. Candeias, C. M. et al. Unexpected outcome (positive or negative) including adverse drug reactions: Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin. *BMJ Case Reports* 2010 (2010).
119. Candeias, C. M. et al. Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin. *BMJ case reports* 2010, bcr0820092157 (2010).
120. Caiado, J., Ribeiro, J., Luis, I., Barbosa, M. & Costa, L. in *Ann Oncol.* 180-180 (OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND).
121. Brown, J. E., Cook, R. J., Lipton, A., Costa, L. & Coleman, R. E. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. *Breast cancer research and treatment* 123, 767-779 (2010).
122. Body, J. et al. in *Bone.* S311-S312 (ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA).
123. Aapro, M., Saad, F. & Costa, L. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. *The oncologist* 15, 1147-1158 (2010).
124. Vitor, R. F. et al. 99mTc-tricarboxyl complexes functionalized with anthracenyl fragments: Synthesis, characterization, and evaluation of their radiotoxic effects in murine melanoma cells. *Cancer Biotherapy and Radiopharmaceuticals* 24, 551-563 (2009).
125. Luis, I. et al. 5083 Interaction between bisphosphonates and taxanes in patients with metastatic bone disease. *European Journal of Cancer Supplements* 7, 285 (2009).
126. Costa, L. & Major, P. P. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. *Nature clinical practice Oncology* 6, 163-174 (2009).
127. Costa, L. & Guise, T. 5148 Emerging recommendations for the prevention of cancer treatment-induced bone loss in women with breast cancer. *European Journal of Cancer Supplements* 7, 304 (2009).
128. Casimiro, S. et al. in *Cancer research.* 172S-172S (AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA).
129. Casimiro, S. et al. (AACR, 2009).
130. Caiado, J., Rodrigues, T., Pedro, E., Costa, L. & Barbosa, P. M. Drug desensitisation in oncology: the experience of a Portuguese immunoallergology department with platins and taxanes. *Allergy: European Journal of Allergy and Clinical Immunology* 64, 293-294 (2009).
131. Caiado, J., Rodrigues, T., Pedro, E., Costa, L. & Barbosa, M. P. Dessensibilização a fármacos em oncologia: Experiência de um Serviço de Imunoalergologia. *Rev Port Imunoalergologia* 17, 57-74 (2009).
132. Alves, A. R., Costa, L., Ferreira, A., Ventura, M. & Riscado, V. P0769 PRIMARY LEFT PSOAS ABSCESS: AN UNUSUAL CASE REPORT. *European Journal of Internal Medicine* 20, S250-S251 (2009).

133. Ribeiro, J. et al. Fulvestrant in metastatic breast cancer previously treated with aromatase inhibitors. *European Journal of Cancer Supplements* 6, 180 (2008).
134. Luís, M. & Costa, L. Total Pain in Patients With Bone Metastases. *Palliative Medicine* 22, 477 (2008).
135. Leitzel, K. et al. in *Clinical & experimental metastasis*. 49-49 (SPRINGER VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS).
136. Costa, L., Badia, X., Chow, E., Lipton, A. & Wardley, A. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. *Supportive Care in Cancer* 16, 879-889 (2008).
137. Costa, L. et al. in *Clinical & experimental metastasis*. 37-37 (SPRINGER VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS).
138. Casimiro, S. et al. P38. RANKL plays a role in migration and invasion of the bone-seeking cell line MDA-MB-231-BO2 and regulates MMP1 and MMP9 expression. *Cancer treatment reviews* 34, 27-28 (2008).
139. Barroso, S. et al. Guidelines for prevention of febrile neutropenia. *Acta Médica Portuguesa* 21, 7-19 (2008).
140. Alho, I. et al. Low molecular weight protein tyrosine phosphatase genetic polymorphism and susceptibility to cancer development. *Cancer genetics and cytogenetics* 181, 20-24 (2008).
141. Alho, I. et al. in *Anticancer research*. 3191-3191 (INT INST ANTICANCER RESEARCH EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE).
142. Aapro, M. et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. *Ann Oncol* 19, 420-432 (2008).
143. Masetti, I. Q., Costa, A. P. D. S., Costa, L. C. S. & Ribeiro, J. E. D. (Google Patents, 2007).
144. Leitzel, K. et al. (AACR, 2007).
145. Felix, J. et al. Direct hospital costs of skeletal-related events (SRE) in Portuguese patients (pts) with breast cancer (BC) and bone metastases. *Journal of Clinical Oncology* 25, 17084-17084 (2007).
146. Costa, L. & Chen, Y.-M. P141 Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate. *The Breast* 16, S53 (2007).
147. Costa, L. & Chen, Y.-M. in *Breast*. S53-S53 (CHURCHILL LIVINGSTONE JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND).
148. Costa, L. et al. 309 POSTER Serum matrix metalloproteinase 1 (MMP1) as a prognostic marker in bone metastases (BM) treated with bisphosphonates. *European Journal of Cancer Supplements* 5, 59 (2007).
149. Costa, L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. *The Breast* 16, 16-20 (2007).
150. Costa, L., Quintela, A., Rodrigues, T., Pinto, A. & Távora, I. in *NEUROENDOCRINOLOGY*. 32-32 (KARGER ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND).
151. Costa, L., Lipton, A. & Coleman, R. E. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. *Supportive cancer therapy* 3, 143-153 (2006).
152. Costa, L., Chen, Y.-M. & Shirina, N. in *Ann Oncol*. 79-79 (OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND).
153. Costa, L. & Chen, Y. Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate. *Breast cancer research and treatment* 100, S62 (2006).

154. Costa, L. et al. Serum carboxyterminal telopeptide (ICTP) as a prognostic marker in bone metastases (BM) treated with bisphosphonates. *Journal of Clinical Oncology* 24, 10107-10107 (2006).
155. Castelbranco, O. et al. Apendicite aguda como manifestação inaugural de neoplasia gástrica. *Jornal Português de Gastrenterologia* 13, 186-190 (2006).
156. Carvalho, A. S. et al. in *GLYCOBIOLOGY*. 1124-1124 (OXFORD UNIV PRESS INC JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA).
157. Kim, C. et al. in *JOURNAL OF BONE AND MINERAL RESEARCH*. P72-P72 (AMER SOC BONE & MINERAL RES 2025 M ST, NW, STE 800, WASHINGTON, DC 20036-3309 USA).
158. Demers, L. et al. in *JOURNAL OF BONE AND MINERAL RESEARCH*. P69-P69 (AMER SOC BONE & MINERAL RES 2025 M ST, NW, STE 800, WASHINGTON, DC 20036-3309 USA).
159. Costa, L. et al. in *Cancer treatment reviews*. S47-S47 (WB SAUNDERS CO LTD 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND).
160. Costa, L. et al. in *JOURNAL OF BONE AND MINERAL RESEARCH*. P54-P55 (AMER SOC BONE & MINERAL RES 2025 M ST, NW, STE 800, WASHINGTON, DC 20036-3309 USA).
161. Ali, S. et al. in *JOURNAL OF BONE AND MINERAL RESEARCH*. P62-P63 (AMER SOC BONE & MINERAL RES 2025 M ST, NW, STE 800, WASHINGTON, DC 20036-3309 USA).
162. Ali, S. et al. in *EJC SUPPLEMENTS*. 247-247 (PERGAMON-ELSEVIER SCIENCE LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND).
163. Costa, L. et al. in *JOURNAL OF BONE AND MINERAL RESEARCH*. 1574-1574 (AMER SOC BONE & MINERAL RES 2025 M ST, NW, STE 800, WASHINGTON, DC 20036-3309 USA).
164. Costa, L. et al. Parathyroid hormone-related protein (PTHrp) expression in human bone metastases (BM). *Journal of Clinical Oncology* 22, 9696-9696 (2004).
165. Ali, S. et al. in *JOURNAL OF BONE AND MINERAL RESEARCH*. 1592-1592 (AMER SOC BONE & MINERAL RES 2025 M ST, NW, STE 800, WASHINGTON, DC 20036-3309 USA).
166. Ali, S. et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. *Ann Oncol* 15, 455-459 (2004).
167. Silva, J. S. et al. P446 Paraneoplastic thromboembolism—case presentation. *European Journal of Internal Medicine* 14, S157 (2003).
168. Demers, L. M., Costa, L. & Lipton, A. Biochemical markers and skeletal metastases. *Clinical orthopaedics and related research* 415, S138-S147 (2003).
169. Costa, L. et al. ORIGINAL REPORTS-Tumor Biology-Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status. *Journal of Clinical Oncology* 20, 850-856 (2002).
170. Costa, L. et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. *Journal of Clinical Oncology* 20, 850-856 (2002).
171. Mandal, M. et al. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. *Journal of Biological Chemistry* 276, 9699-9704 (2001).
172. LIPTON, A., COSTA, L., ALI, S., LEITZEL, K. & DEMERS, L. BIOCHEMICAL MARKERS AND SKELETAL METASTASES. *Journal of bone and mineral metabolism* 19, 81 (2001).
173. Lipton, A., Costa, L., Ali, S. & Demers, L. Bone markers in the management of metastatic bone disease. *Cancer treatment reviews* 27, 181-185 (2001).

174. Lipton, A., Costa, L., Ali, S. & Demers, L. in Seminars in oncology. 54-59 (Elsevier).
175. Ali, S. et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. Journal of clinical oncology 19, 3434-3437 (2001).
176. Ali, S. et al. Effect of elevated serum carboxyterminal telopeptide (ICTP) on survival in breast cancer patients with and without bone metastases. European journal of cancer 37, S180 (2001).
177. Demers, L. M., Costa, L. & Lipton, A. Biochemical markers and skeletal metastases. Cancer 88, 2919-2926 (2000).
178. Ali, S. et al. Effect of Elevated Serum Carboxyterminal Telopeptide (ictp) on Survival in Breast Cancer Patients with Only Bone Metastases. Breast cancer research and treatment 64, 44 (2000).
179. Lipton, A. et al. Markers of bone resorption in patients treated with pamidronate. European journal of cancer 34, 2021-2026 (1998).
180. Curley, E. et al. Monitoring treatment of bone metastases. European journal of cancer 33, S148-S149 (1997).
181. Lipton, A., Costa, L. & Demers, L. Bone markers in osteoporosis and malignancy. The Canadian journal of oncology 5, 11-15 (1995).
182. Demers, L. et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clinical chemistry 41, 1489-1494 (1995).
183. Costa, L. et al. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma. Cancer 85(1), 100-103 (1999).
184. Costa, L., Moreira, C. & da Costa, E. B. Disodium pamidronate (APD) in the treatment of bone metastases. Acta Médica Portuguesa 6, 71-73 (1993).
185. Body, J.-J. et al. Update on the Role of Bisphosphonates in Metastatic Breast Cancer.

Invited Lectures (selection of the last 15 years)

- *What do Bone Markers tell us about Clinical Status and Pathophysiology in Bone Metastases?*, M.D. Anderson Cancer Center, USA, December 2003
- *Endocrine Therapy in Breast Cancer: Clinical Aspects*, XIV Porto Cancer Meeting, O’Porto, Portugal; April 2004
- *Parathyroid Hormone-related Protein (PTHrP) in Breast Cancer Metastasis*, M.D. Anderson Cancer Center, USA, December 2004
- *The Role of Bisphosphonates in Breast Cancer*, Second Central European Cooperative Oncology Group, Vienna, Austria, June 2005
- *Coosing the Optimum Treatment for Bone Complications*, 17th MASCC (Multinational Association of Supportive Care in Cancer), Geneve, Switzerland, July 2005
- *The Role of RANK Ligand in Cancer-induced Bone Disease*, Expanding Therapeutic Options in Oncology, Vienna, Austria, September 2006

- *Bone Metastasis: Preserving Patient Functional Independence*, European Society of Medical Oncology, Istanbul, Turkey, September 2006
- *Maintaining patient autonomy: management of metastatic disease*, Third Educational Breast Care Meeting, Barcelona, Spain, May 2007
- *Adjuvant Hormonal Treatment of Breast Cancer*, 20th European Congress of Obstetrics and Gynecology, Lisbon, Portugal, March 2008
- *Optimizing bisphosphonate therapy in breast and prostate cancers: How to better prevent bone complication?* Oncology Grand Rounds, University of Alberta, Edmonton, Canada, September 2008
- *Clinical Impact of Bone-Targeted Therapies in Cancer*, Gregorio Marañón Hospital, Madrid, Spain, January 2011
- *Established Benefits of Bisphosphonates in Early Breast Cancer*, Special Lecture, 8th Kyushu Regional Meeting of the Japanese Breast Cancer Society, Japan, February 2011
- *Metastases Prevention in Breast Cancer*, Skeletal Care Academy, Madrid, Spain, February, 2011
- *Molecular Therapy in Breast Cancer with Bone Metastases*, 1st Global Cancer Genomics Consortium TMC Symposium: the interface between genomics and cancer medicine. Mumbai, India, 2011
- *mTOR pathway: a common target in cancer or just a co-target ?* XXI Porto Cancer Meeting, O'Porto, Portugal, April 2012
- *Clinical Impact of Bone-Targeted Therapies in Patients with Bone Metastases*, Grand Rounds of Oncology, Cancer Care Manitoba – University of Manitoba, Winnipeg, Canada, May 2012
- *Bone-Targeted therapies in Bone Metastases: clinical impact and expectations*. Grand Rounds of Hematology & Oncology, Princess Margaret Hospital, Toronto, Canada, May 2012
- *A new era in skeletal health for patients with solid tumors*, The science behind the success, 3rd International Lung Cancer Seminar, Tinos Island, Greece, September 2012
- *Accelerating drug discovery: from bench to bedside*, Young Master Class, 37th ESMO congress, Vienna, Austria, September 2012
- *Management of Bone Metastases*, St. Vincent's University Hospital, Dublin, Ireland, March 2013
- *Improving the medical management of bone metastases, Challenging Metastatic Cancer: Remodeling Management - Evolution or Revolution*, Royal College of Physicians, London – Kesington Forum, London, UK, April 2013
- *Oncologic treatment of tumors with disorders of the ALK gene*, European Congress of Pathology, Lisbon, Portugal, September 2013
- *Difficulties in Pharmacogenomics Clinical Studies in Cancer*, 3rd ESPT Pharmacogenomics Advanced Training Course, Lisbon, Portugal, September 2013
- *Treatment of bone metastases from breast cancer*, Innovation in Breast Cancer – IBC 2014, Madrid, Spain, February 2014

- *Re-visiting the vicious cycle in bone metastases: Host Variability and Oncodynamics*, Ottawa Hospital Research Institute Seminar, Ottawa, Canada, April 2015
- *Current & Novel Therapies for Bone Metastases - Moving away from bone-targeted agents? Current agents, indicators of response, sensitivity and resistance*, 2014 Bonus 9 Meeting, Ottawa Hospital Cancer Centre, Ottawa, Canada, April 2015
- *The current status of treatment of cancer-related bone disease*, Haukeland University Hospital, Bergen, Norway, May 2014
- *An update in the management of bone metastases in patients with solid tumours: overview of the clinical data and practicalities of management*, Healthcare Professionals at the Royal College of Obstetricians and Gynecologists, London, UK, June 2014
- *Cancer Metastases: is bone a useful paradigm?* 1st ASPIC International Congress, Lisbon, Portugal, November 2014
- *New therapies and approaches in cancer-induced bone disease. Clinical debate: Radium-223 can augment the efficacy of cancer and bone treatments for metabolic bone disease*, ECTS & IBMS Joint Meeting 2015, Rotterdam, The Netherlands, April 2015
- *Mechanisms of Resistance in Breast Cancer*, UMIB-SUMMIT, O'Porto, Portugal, September 2015
- *Molecular Mechanisms in metastases in breast cancer-is bone a useful paradigm?*, Annual Breast Cancer Conference, Oslo, Norway, October 2015
- *Prognostic Biomarkers in Metastatic Breast Cancer*, Cancer Genomics and Biology 2015, Jiu Jiang University, China, November 2015
- *Nanomedicine in Cancer: what we can offer so far*, NWCD16, INL - International Iberian Nanotechnology Laboratory, Braga, Portugal, February 2016
- *Cancer and metastases: is bone a useful paradigm?*, INSERM UMR 1033, Lyon, France, April 2016
- *Breast Cancer And Bone Metastasis – Do We Still Have A Problem?*, CABS-ECTS, Rome, Italy, May 2016
- *Blood markers as endpoints, Inclusion of Breast Cancer Patients with Bone-only Metastasis in Clinical Trials Consensus Development Meeting*, ASCO-FDA Meeting, Chicago, USA, June 2016
- *New drug toxicity*, ESMO Update for Practising Oncologists 2017, Lisbon, Portugal, March 2017
- *Cancer Research: A Selection of "Hot Spots"*, Instituto Português de Oncologia- Portuguese League Against Cancer, Lisbon, Portugal, April 2017.
- *Bone Health in Curable Breast Cancer*, Leaping Forward Meeting, Lisbon, Portugal, May 2017
- *Liquid Biopsies in Clinical Oncology: how many dimensions and how much dynamics?*, 24th Cancer Porto Meeting, Portugal, May 2017
- *Breast Cancer Diagnosis and Treatment: Still on the Road to improve Results*, 3rd ESOP-ESO Advanced Master Class in Oncology Pharmacy, Lisbon, Portugal, May 2017.